Hepatitis C Drug Pricing Targeted With HIV-Style Activism In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead’s Sovaldi likely will face a tough time in front of pricing and reimbursement authorities in cash-strapped European countries.